EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial

Christine A Shaw, Runa Mithani, Archana Kapoor, Rakesh Dhar, Lauren Wilson, Laila El Asmar, Sabine Schnyder-Ghamloush, Kristi Schaefers, Allison August, Sonia K Stoszek, Grace L Chen

The Journal of Infectious Diseases · 23.09.2024 · 230 (3) · e637-e646

DOI: 10.1093/infdis/jiae035 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 31.01.2024. Verfasst von Christine A Shaw und 10 weiteren Autor:innen. Beteiligte Einrichtung: Moderna, Inc, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus Infections, Antibodies, Viral, Antibodies, Neutralizing. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Moderna, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Respiratory syncytial virus (RSV) presents a global health concern. A lipid nanoparticle–encapsulated mRNA-based RSV vaccine (mRNA-1345) that encodes the membrane-anchored RSV prefusion–stabilized F glycoprotein is under clinical investigation.

Methods

This phase 1 dose escalation study was based on a randomized, observer-blind, placebo-controlled design, and it assessed the safety and immunogenicity of mRNA-1345 in healthy adults aged 18 to 49 years. Participants were randomized to receive 1 dose of mRNA-1345 (50, 100, or 200 µg) or placebo or 3 doses of mRNA-1345 (100 µg) or placebo 56 days apart. Results mRNA-1345 was well tolerated at all dose levels. The most common solicited adverse reactions were pain, headache, fatigue, myalgia, or chills, which were all generally mild to moderate. At 1 month postinjection, a single injection of mRNA-1345 boosted RSV neutralizing antibody titers (geometric mean fold rise: RSV-A, 20.0–23.5; RSV-B, 11.7–16.0) and RSV prefusion binding antibody concentrations (geometric mean fold rise, 16.1–21.8), with no apparent dose response. Antibody levels remained above baseline through 6 months. Sequential doses of 100 µg were well tolerated but did not further boost antibody levels.

Conclusions

A single mRNA-1345 injection demonstrated an acceptable safety profile in younger adults and induced a durable neutralizing antibody response, supporting its continued development. Clinical Trials Registration ClinicalTrials.gov NCT04528719.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus VaccinesRespiratory Syncytial Virus InfectionsAntibodies, ViralAntibodies, NeutralizingHumansAdultYoung AdultMaleFemaleAdolescentMiddle AgedRespiratory Syncytial Virus, HumanRNA, MessengerHealthy VolunteersNanoparticlesImmunogenicity, VaccinemRNA Vaccines

Stichwörter der Autor:innen

mRNA vaccinemRNA-1345respiratory syncytial virussafety and immunogenicityyounger adult

Substanzen

Respiratory Syncytial Virus VaccinesAntibodies, ViralAntibodies, NeutralizingRNA, MessengermRNA Vaccines

Autor:innen und Institutionen

  • Moderna, Inc, Cambridge, Massachusetts, USA.

Förderung

  • Moderna, Inc

Zitieren

APA

Shaw, C. A., Mithani, R., Kapoor, A., Dhar, R., Wilson, L., El Asmar, L., Schnyder-Ghamloush, S., Schaefers, K., August, A., Stoszek, S. K., & Chen, G. L. (2024). Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial. The Journal of Infectious Diseases, 230(3), e637-e646. https://doi.org/10.1093/infdis/jiae035

Vancouver

Shaw CA, Mithani R, Kapoor A, Dhar R, Wilson L, El Asmar L, et al. Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial. The Journal of Infectious Diseases. 2024;230(3):e637-e646. doi:10.1093/infdis/jiae035

BibTeX
@article{Shaw2024,
  author = {Shaw, Christine A and Mithani, Runa and Kapoor, Archana and Dhar, Rakesh and Wilson, Lauren and El Asmar, Laila and Schnyder-Ghamloush, Sabine and Schaefers, Kristi and August, Allison and Stoszek, Sonia K and Chen, Grace L},
  title = {Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  volume = {230},
  number = {3},
  pages = {e637--e646},
  doi = {10.1093/infdis/jiae035}
}
Kostenlos starten →